CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024
Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value …
Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value …
While the outlook for vaccines in the US looks bleak under the current administration, the UK Government is pressing ahead …
US-based Actio Biosciences has closed a Series B financing round, raising $66m to advance the genetics-driven small molecule therapeutics pipeline …
BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory …
In a final blow to Eli Lilly’s Kisunla (donanemab) and Eisai’s Leqembi (lecanemab) UK reimbursement prospects, the National Institute for …
Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to advance its portfolio of next-generation therapies …
The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) …
With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics. At …
Denmark-based Bavarian Nordic has sold a priority review voucher (PRV) for $160m, a day after the US Food and Drug …
Tisento Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its investigational oral medicine, …
US Food and Drug Administration (FDA) Commissioner Dr. Marty Makary addressed concerns about the recent cuts impacting the agency’s ability …
India and the US are on the verge of a trade agreement that will transform commerce between the two largest …
Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients …
Orion Corporation has broadened its partnership with Glykos, focusing on the development of antibody-drug conjugates (ADCs). Under the research partnership and …
The US Food and Drug Administration (FDA) has created a new priority review voucher (PRV) framework to expedite the drug …